HIV Vaccine Research Update and HVTN 505

HIV Vaccine Research Update and HVTN 505

May 21, 2013 • 0 comments • By Miguel Gomez, Director, AIDS.gov, and Senior Communications Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human Services

May 18th was HIV Vaccine Awareness Day, and we wanted to remind you of several posts we did last week on that subject.

On Friday, we featured a guest post, Moving Forward on HIV Vaccine Awareness Day, by Dr. Nelson Michael, director of the U.S. Military HIV Research Program. And then we posted this video interview with Dr. Carl Dieffenbach, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH). We ended the day with a cross-post of NIH’s bulletin for HIV Vaccine Awareness Day.

Today, we would like to share another video interview we did with Dr. Dieffenbach on the importance of vaccine research and on the HVTN 505 study, which was discontinued by NIH last month.

For more information about the HVTN 505 study, please see NIAID’s updated Questions and Answers and read the news release cross-posted on AIDS.gov. To learn about NIAID’s HIV vaccine research, please see the HIV vaccine section of the NIAID website.

Related posts:

1. May 18th HIV Vaccine Awareness Day (HVAD): A Conversation with Dr. Carl Dieffenbach
2. HIV Vaccine Awareness Day Bulletin
3. NIH Research Update: Treating HIV-infected People with Antiretrovirals Protects Partners from Infection
4. Future Directions for NIAID’s HIV Vaccine Clinical Research
5. Statement: NIH Discontinues Immunizations in HIV Vaccine Study